Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuli Wang

Showing results (441-450 of 447) with videos related to

Pageof 45
Sort By:
You have reached the last page of results.This site can display upto 447 results.
Nature Medicine|June 25, 2015
Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and AktJustin E Wilson, Alex S Petrucelli, Liang Chen, et al.
Radiology|August 5, 2025
MRI-based Ovarian Lesion Classification via a Foundation Segmentation Model and Multimodal Analysis: A Multicenter StudyWen-Chi Hsu, Yuli Wang, Yu-Fu Wu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 7, 2025
Artificial intelligence-based lesion characterization and outcome prediction of prostate cancer on [<sup>18</sup>F]DCFPyL PSMA imagingLinmei Zhao, Maliha R Imami, Yuli Wang, et al.
Future Oncology (London, England)|October 30, 2025
Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational studyHua Zhong, Shunjun Jiang, Wenxiu Yao, et al.
Cellular and Molecular Gastroenterology and Hepatology|June 21, 2020
Decreased Colonic Activin Receptor-Like Kinase 1 Disrupts Epithelial Barrier Integrity in Patients With Crohn's DiseaseTakahiko Toyonaga, Erin C Steinbach, Benjamin P Keith, et al.
Molecular Cancer Therapeutics|November 5, 2021
SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug ResistanceKristen Jensen-Pergakes, John Tatlock, Karen A Maegley, et al.
Journal of Medicinal Chemistry|March 14, 2017
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFRSimon Planken, Douglas C Behenna, Sajiv K Nair, et al.
Pageof 45

Showing results (441-450 of 447) with videos related to

Sort By:
Pageof 45
You have reached the last page of results.This site can display upto 447 results.
Nature Medicine|June 25, 2015
Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and AktJustin E Wilson, Alex S Petrucelli, Liang Chen, et al.
Radiology|August 5, 2025
MRI-based Ovarian Lesion Classification via a Foundation Segmentation Model and Multimodal Analysis: A Multicenter StudyWen-Chi Hsu, Yuli Wang, Yu-Fu Wu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 7, 2025
Artificial intelligence-based lesion characterization and outcome prediction of prostate cancer on [<sup>18</sup>F]DCFPyL PSMA imagingLinmei Zhao, Maliha R Imami, Yuli Wang, et al.
Future Oncology (London, England)|October 30, 2025
Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational studyHua Zhong, Shunjun Jiang, Wenxiu Yao, et al.
Cellular and Molecular Gastroenterology and Hepatology|June 21, 2020
Decreased Colonic Activin Receptor-Like Kinase 1 Disrupts Epithelial Barrier Integrity in Patients With Crohn's DiseaseTakahiko Toyonaga, Erin C Steinbach, Benjamin P Keith, et al.
Molecular Cancer Therapeutics|November 5, 2021
SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug ResistanceKristen Jensen-Pergakes, John Tatlock, Karen A Maegley, et al.
Journal of Medicinal Chemistry|March 14, 2017
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFRSimon Planken, Douglas C Behenna, Sajiv K Nair, et al.
Pageof 45